Agilent Introduces Unique Next Generation Sequencing-based Preimplantation Genetic Testing (PGT) Solution
October 31 2018 - 11:00AM
Business Wire
Agilent OnePGT solution empowers fertility specialists to
attain comprehensive insights to improve the ranking of in vitro
fertilized (IVF) embryos
Agilent Technologies Inc. (NYSE: A) today announced the
introduction of Agilent OnePGT, a genome-wide, next-generation
sequencing (NGS) solution for preimplantation genetic testing
(PGT). OnePGT allows parallel detection of multiple monogenic
disorders (PGT-M), translocations (PGT-SR), and aneuploidies
(PGT-A) on a single biopsy. Agilent will showcase the OnePGT
solution at the 5th Congress on Controversies in Preconception,
Preimplantation and Prenatal Genetic Diagnosis (CoGEN), November
1-3, 2018 in Paris, France.
OnePGT guides the laboratory from biopsy material to a single
comprehensive report in a matter of days. Empowered by Agilent’s
Alissa platform, data analysis is streamlined by the optimized and
verified pipelines, allowing automatic calling of genetic
abnormalities with built-in quality control metrics and audit
trail. This innovative solution provides fertility specialists the
ability to more easily achieve comprehensive PGT data in which to
support enhanced embryo ranking, identifying the best quality
embryos for transfer.
“By providing highly accurate and comprehensive genetic data,
OnePGT enables fertility specialists, and the couples they assist,
to make better-informed decisions on embryo ranking and
selection—thereby increasing the chances of having a successful and
healthy pregnancy,” said Kamni Vijay, vice president, and general
manager, Agilent Genomics Division. “At Agilent, we aim to offer
labs a complete, integrated workflow that is easy to use, and
provides accurate data for comprehensive insights.”
Vijay also noted that for labs currently performing just one
type of test, OnePGT provides them the opportunity to expand their
offerings in this growing market without significantly increasing
the lab’s footprint or resources.
“With the Agilent OnePGT solution we can now perform concurrent
PGT-M/-A/-SR and obtain comprehensive genetic information, more
quickly, using a single biopsy,” said Dr. Richard Choy, Director,
Preimplantation Genetic Diagnosis Laboratory, Chinese University of
Hong Kong. “Not only does the single universal workflow increase
the genetic information available for each embryo, but it has also
increased our lab’s efficiency due to a single platform to
maintain.”
According to recent data, the average age of first-time mothers
has risen to over 30 years of age. As the maternal age at
conception increases, the chance of chromosomal abnormalities
within the embryo also increase leading to lower implantation rates
and increased rate of miscarriages. The comprehensive data achieved
with Agilent OnePGT can help fertility specialists improve the
chances of selection of the most viable and healthy embryos for
subsequent transfer.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life
sciences, diagnostics, and applied chemical markets. With more than
50 years of insight and innovation, Agilent instruments, software,
services, solutions, and people provide trusted answers to
customers' most challenging questions. The company generated
revenues of $4.47 billion in fiscal 2017 and employs 14,500 people
worldwide. Information about Agilent is available at
www.agilent.com. To receive the latest Agilent news, subscribe to
our Newsroom. Follow Agilent on Linked In, Twitter, and
Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181031005481/en/
Agilent TechnologiesNaomi Goumillout,
+1-781-266-2819naomi.goumillout@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Apr 2023 to Apr 2024